Applying Precision Medicine to the Active Surveillance of Prostate Cancer

Chad A. Reichard, MD; Andrew J. Stephenson, MD; and Eric A. Klein, MD

The recent introduction of a variety of molecular tests will potentially reshape the care of patients with prostate cancer. These tests may make more accurate management decisions possible for those patients who have been “overdiagnosed” with biologically indolent disease, which represents an exceptionally small mortality risk. There is a wide range of possible applications of these tests to different clinical scenarios in patient populations managed with active surveillance. Cancer 2015;121:3403-11. © 2015 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

KEYWORDS: prostate cancer, active surveillance, gene expression, biomarker.

INTRODUCTION

The burgeoning area of molecular risk assessment (gene expression profiling and/or proteomic tests) in the diagnosis and treatment of prostate cancer is rapidly illuminating how clinicians might more accurately select the right treatment for the right patient at the right time. Treatment and patient selection and treatment timing form the framework in which clinically available molecular risk profiling tests potentially enhance traditional clinical decision-making. Historically, treatment selection indicated which definitive therapy was chosen (prostatectomy, radiotherapy, etc) and did not include active monitoring of a newly diagnosed patient. Recently, the relative long-term safety of active surveillance (AS) in patients selected based on clinical criteria has been reported. The aforementioned molecular tests have concomitantly been evaluated with respect to the similar, but not entirely equivalent, clinical question: which individual needs treatment? The answer lies in the fact that these tests enable management decisions based on the biologic potential of an individual’s tumor, thereby allowing a precision medicine approach to the management of patients with early-stage prostate cancer. Accurate assessment of patients’ suitability for AS is important at the population level as well. It is expected that 220,800 cases of prostate cancer will be diagnosed in 2015. Recent analyses have demonstrated that the percentage of these cancers that are low risk and/or with a Gleason score ≤6 ranges from 22% to 50%, and the majority of these patients are likely candidates for AS. However, an estimated 90% of newly diagnosed patients will undergo definitive therapy, highlighting the need to expand AS programs. Herein, we attempted to outline the rationale for the use of molecular risk assessment during counseling of patients regarding AS and posited specific ways in which initial and serial testing might be of value to patients who are managed with AS for increasing lengths of time.

Prostate-Specific Antigen Screening

Before the introduction of prostate-specific antigen (PSA) screening in the early 1990s, observational data suggested that approximately one-half of newly diagnosed prostate cancer cases were locally advanced or metastatic, and that within 5 years of extensive PSA screening this rate decreased to 5%. Due to this precipitous decline in the number of patients initially presenting with incurable disease, along with the belief that all prostate cancer was potentially lethal, continued widespread screening resulted. The practice of screening all men annually starting at age 50 years and continuing indefinitely (which was and in many areas still is a common practice pattern) has resulted in the current issues of overdiagnosis (ie, finding tumors on core needle biopsy performed due to rising PSA that pose no threat to a patient’s overall life expectancy) and overtreatment (administration of definitive local therapy without any evidence of a mortality benefit). These issues are
why, in part, the US Preventive Services Task Force determined PSA screening to be a grade D recommendation, stating that the risks of screening outweigh the benefits. However, this blanket recommendation has not been without controversy, given the nuances of trial design, population characteristics, and subanalyses of what to our knowledge are the 2 most methodologically sound studies of PSA screening to date (the Prostate, Lung, Colorectal and Ovarian [PLCO] Cancer Screening Trial and European Randomized Study of Screening for Prostate Cancer ERPC). In addition, worries regarding an increase in avoidable cancer deaths in the absence of screening remain. Nevertheless, the current paradigm is to avoid overtreatment simply by screening no one.

Several recently developed tests such as prostate cancer antigen 3 (PCA3), the 4Kscore (OPKO Health Inc, Miami, Fla), and the Prostate Health Index attempt to more accurately assess, before biopsy, the risk of biologically significant cancer. These tests will aid in avoiding the initial detection of indolent disease, which will help to address the problem of overdiagnosis and, by default, overtreatment. However, for the patients who still undergo biopsy, it is equally important to separately address the problem of overtreatment. The available data suggest that AS is safe for the properly selected patient (ie, one with an indolent tumor and a life expectancy limited by competing causes [age, comorbidity, etc]). The clinical challenge is to increase the accuracy of this selection process. This challenge is met with additional information gleaned from the newly available tests reviewed below (Table 1).

**Molecular Risk Assessment as AS Entry Criteria**

An individual patient’s comfort with AS as a “treatment” course depends directly on the confidence of both the provider and the patient in the accuracy of the assessment of disease indolence based on prostate biopsy. Although there is ample evidence to indicate that Gleason score 6 cancers and select Gleason score 7 cancers are associated with low mortality and morbidity in the absence of therapy (particularly for those individuals with a limited life expectancy), concerns regarding the heterogeneity of clinical behavior within these subgroups and understaging and undersampling issues limit the appeal of surveillance for both patients and physicians. It is extremely difficult to know if a needle biopsy that indicates a small focus of low-grade tumor is representative of the entire prostate. For example, increased diagnosis of higher-grade tumors in the often undersampled prostatic apex has been demonstrated. Molecular risk assessment tests have been developed prospectively with tumor heterogeneity in mind, as well as validated retrospectively to account specifically for these biopsy-related issues. Current clinical criteria for AS vary among cohorts, but the majority include parameters such as clinical stage ≤T2a disease, a PSA level ≤10 ng/mL, Gleason score ≤3 + 3 tumors (there are groups that include select patients with Gleason score 3 + 4 tumors), ≤2 to 3 total cores positive, and ≤50% single core involvement. However, approximately 20% of patients with very low-risk disease according to the National Comprehensive Cancer Network (NCCN) guidelines still harbor worrisome pathology. This is one reason why it is not surprising that molecular risk assessment tests have been successful in increasing prognostic precision over and above the performance of known significant clinical covariates and nomograms.

**Oncotype DX: genomic prostate score**

The genomic prostate score (GPS) (Oncotype DX; Genomic Health, Redwood City, Calif) is comprised of a 17-gene panel derived from representative tumorigenesis pathways prospectively selected based on their combined ability to predict for clinical disease recurrence, death from prostate cancer, and adverse pathology at the time of prostatectomy regardless of whether the tissue analyzed was from the highest Gleason pattern present. The individual gene expression levels are measured as described previously in a minimum sample of 1 mm of tumor and combined algorithmically into the GPS. The GPS is then applied according to the patient’s NCCN risk group, giving a predicted percent likelihood of favorable...
pathology. In the first clinical validation study, a cohort of men eligible for AS based on clinical criteria, but who underwent early prostatectomy, were analyzed. Consideration of significant clinical covariates in this cohort did not diminish the ability of GPS to predict high-grade and/or non-organ-confined pathology. The odds ratio (OR) for each 20-point increase in GPS adjusted for the continuous University of California at San Francisco Cancer of the Prostate Risk Assessment (CAPRA) score was 2.1 (95% confidence interval [95% CI], 1.4-3.2); when adjusted for NCCN risk group, the OR was 1.9 (95% CI, 1.3-2.8) and when adjusted for age, PSA, clinical stage of disease, and biopsy Gleason score, the OR was 1.9 (95% CI, 1.2-2.8). This demonstrated that the GPS adds additional clinically meaningful predictive value to prior validated multivariable risk stratification tools. The GPS was also found to be predictive of time to biochemical disease recurrence (BCR) and adverse pathology at the time of prostatectomy after adjusting for NCCN risk group in an additional validation study. Furthermore, a retrospective analysis of the use of GPS in private practice clinics revealed a 24% absolute increase in AS after GPS scores were used in clinical decision-making. Similarly, a prospective clinical usefulness study reported a 10% absolute increase in AS with the use of GPS.

**ProLaris: cell cycle progression score**

The cell cycle progression (CCP) score (ProLaris; Myriad Genetics, Salt Lake City, Utah) is calculated from an algorithmic analysis of the expression levels of a 46-gene panel in 2 mm to 4 mm of tumor tissue, and is highly correlated with prostate tumor cell proliferation as described previously. In contrast to GPS, the initial development of the CCP score did not account for tumor heterogeneity or biopsy sampling error. However, subsequent retrospective studies have demonstrated preserved predictive value in a biopsy-based setting, despite differences in methodology. A meta-analysis of the CCP score demonstrated its predictive value for disease-specific survival (pooled hazard ratio [HR], 2.08) as well as BCR (pooled HR, 1.63). The CCP score also has been shown to improve on clinical predictive models and add value in real-life clinical decision-making. In surveys of ordering physicians, 32% to 65% of cases demonstrated a change in intended treatment after using the CCP score.

**ProMark: proteomic prognostic test**

The ProMark test (Metamark Genetics Inc, Augusta, Ga) is a protein quantification profile that shares principles similar to those of GPS and CCP with regard to development and application. In the initial biopsy simulation study, it was comprised of 12 proteomic biomarkers that were demonstrated to be predictive of aggressive disease and lethal outcome while accounting for biopsy sampling error. This was achieved by creating biopsy simulation tissue microarrays (TMAs) from the areas of highest and lowest Gleason pattern in prostatectomy sample tissue blocks from a cohort of 380 patients. The final predictive model was then tested in both of these TMAs separately. The area under the curve for disease aggressiveness was 0.72 (95% CI, 0.64-0.79) for the low TMA and 0.70 (95% CI, 0.62-0.77) for the high TMA. The areas under the curve were similarly concordant between high and low TMA for lethal outcome. In a subsequent blinded validation study of an 8-biomarker assay derived from the initial markers, the ProMark test improved on clinical risk stratification tools. At a risk score of 0.33, the likelihood of favorable pathology (surgical Gleason score of ≤3 + 4 and organ-confined disease ≤T2) for the NCCN very low-risk and low-risk groups was 95% and 81.5%, respectively, compared with 80.3% and 63.8%, respectively, using the clinical criteria alone. A similar improvement on the D’Amico low-risk criteria was observed as well.

**Cost concerns**

Although the list price of these tests can range in the several thousands of dollars, currently it has been our experience that the out-of-pocket cost to the patient ranges from nothing to a few hundred dollars. As these tests are more widely adopted, increasing coverage by insurance companies can be anticipated, and in the interim there are cost assistance programs available to help mitigate the expense to patients. In addition, we would argue that if the use of these test means getting a clinical decision right the first time, that is ultimately the most cost-effective strategy.

**Challenges in the validation of molecular risk profiling tests in AS populations**

Even the longest follow-up report in what to our knowledge is one of the largest available AS cohorts does not enable us to determine exactly which patients died of prostate cancer specifically because their choice of surveillance abrogated their chance for cure, as noted by Cooperberg. The studies that are necessary to definitively answer this question may never be performed. However, the available data regarding the added predictive value of molecular risk tests compared with the clinical entry criteria alone used in currently maturing AS series suggests it may be possible to reduce an already low long-term disease-specific mortality risk even further or to maintain this acceptably low
mortality risk while increasing the numbers of patients managed by AS. This “answer by proxy” to the issue raised by Cooperberg relies on the use of molecular risk profiling to more accurately identify, and remove from AS eligibility, men who harbor known risk factors for increased disease-specific mortality that were missed by clinical criteria alone. To this end, the Prolaris and Oncotype DX are now included in the discussion of risk stratification in the latest edition of the NCCN prostate cancer guidelines.

To the best of our knowledge, there are no available, prospective, randomized data that definitively demonstrate which, if any, of these tests outperform current clinical risk stratification in a contemporary AS cohort, nor are there head-to-head comparison data. A multiarm prospective trial of patients choosing AS, randomized to either a molecular profiling test or clinical risk stratification alone to determine final AS eligibility, could more definitively answer some of these unknowns. However, these studies would require lengthy follow-up to examine clinically meaningful endpoints, during which time it is likely that interim technological advances would supplant the test versions used during trial enrollment.

**Molecular Risk Profiling as a Substitute for Early Confirmatory Repeat Biopsy**

Early repeat biopsy as entry criteria into an AS protocol has been widely advocated due to the aforementioned issues of undersampling and understaging. However, a firm consensus regarding timing and type (standard transrectal ultrasonography [TRUS] biopsy vs saturation vs magnetic resonance-ultrasound fusion biopsy) of the repeat evaluation of patients managed by AS does not exist. Some may say that repeat evaluation is unnecessary given the findings in low-risk or older patients in the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) trial and the overall findings of the Prostate Cancer Intervention versus Observation Trial (PIVOT), in which watchful waiting (ie, doing nothing until symptom development) did not appear to confer an increased mortality risk.

Even as this question is debated, the underlying issue remains that repeat biopsy is subject again to the same drawbacks as initial biopsy, including patient discomfort, sampling error, and risk of infection. No patient who has undergone a prostate biopsy desires to repeat the experience unnecessarily, and the need for multiple biopsies may be the determining factor for some patients to elect treatment over continued AS. Furthermore, avoiding a repeat biopsy will avoid the small, but real, risk of urinary sepsis and/or mortality that Ehdaie et al found to be increased after each subsequent biopsy in an AS cohort.

Approximately 1 million prostate biopsies are performed every year in the United States among Medicare patients. If even 10% of these biopsies are for AS, with a conservatively estimated 1% sepsis risk, avoiding them altogether would save 1000 patients from hospitalization annually.

If obtained at the time of the initial biopsy, molecular risk profiling can potentially substitute for the need for early repeat biopsy based on its prior referenced ability to predict the biology of the entire prostate, thereby assuaging concerns regarding undersampling and understaging. Although not initially developed in a predefined AS population, both the GPS and CCP score have been validated in biopsy specimens of patients who meet the clinical criteria for AS. The initial discovery study for ProMark (Metamark Genetics Inc) was also performed in a cohort of patients who were potentially eligible for AS.

In addition, Long et al demonstrated that there is a strong correlation of gene expression across separate biopsy cores from the same patient, a finding that was similar to that of a study by Peng et al that suggested that there was limited, operator choice-dependent variation in gene signature analysis of highly expressed genes across multiple biopsy samples, primary versus secondary Gleason patterns, and primary versus benign tissue. This consistency of gene expression, regardless of interbiopsy or intrabiopsy tumor heterogeneity, reinforces the current understanding that it is possible to be confident in the biology of the entire prostate based on analysis of gene expression in a biopsy sample.

Some may argue that these tests report only a probability of adverse pathology versus repeat biopsy, which directly confirms the absence of unfavorable features (and in turn equates to a low likelihood of important upgrading). However, uncertainty exists with both approaches, and it is currently unclear whether one approach differs substantially in risk from the other. Another concern may be the clinically apparent low-risk patient with a discordantly high-risk test score. In these cases, repeat biopsy may be unavoidable. Although the implementation of concomitant molecular risk profiling with initial TRUS biopsy as a replacement for early repeat biopsy is a nuanced proposition that currently lacks direct comparison data, we believe it to be a reasonable approach given the aforementioned arguments that these tests accurately predict the biologic potential of the entire tumor regardless of sampling error or intratumor heterogeneity.

**Can Molecular Risk Assessment Make for More Intelligent AS Follow-Up?**

There is currently a range of reported follow-up biopsy intervals for patients managed by AS, with no available
data, to our knowledge, supporting the use of one frequency over another and no reports regarding the safety of modifying follow-up intervals based on clinical risk factors.

Although prospective data regarding the stability of individual patients’ molecular risk scores over time have yet to be reported, important inferences can be made from the clinical validation studies that may help to encourage individual tailoring of AS follow-up schedules. In addition to the ability of GPS to predict the initial presence of adverse pathology, both GPS and the CCP score are backed by 15-year follow-up data demonstrating their predictive ability with regard to risk of clinical disease recurrence (GPS) and metastasis-free survival (CCP score). Therefore, one can hypothesize that when applied as prospective selection criteria for an AS cohort, the patients with the lowest likelihood of adverse pathology would also be likely to have the most stable molecular risk scores over time, intuitively demonstrating the possibility of a decreased frequency of monitoring without sacrificing mortality benefit.

In patients who undergo molecular risk stratification at the time of initial diagnosis that demonstrates a low likelihood of adverse pathology, a longer interval to repeat biopsy, or perhaps even conversion to a watchful waiting protocol, could be considered. Conversely, among patients with a higher likelihood of adverse pathology, a shorter interval to repeat biopsy or a more confident decision for immediate treatment may be made. Although this rationale is based on robust retrospective follow-up data, definitive support for this strategy would come in the form of randomization of patients to more intensive or less intensive follow-up based on their molecular risk profile. Molecular risk profiling adds prognostic precision to known clinical parameters; it does not replace them. Clinicians must still exercise judgment regarding the factors of patient life expectancy, comorbidity, and patient desire when using a molecular risk score to help plan the frequency of follow-up in an individualized AS protocol (Fig. 1).

Molecular Risk Assessment Versus Histopathology
Concordance among pathologists with regard to Gleason grading and reporting practices of the extent of cancer varies widely, adding to the difficulty in ensuring uniform and accurate prognostication. McKenney et al examined an AS cohort and demonstrated that there was low interobserver reproducibility with regard to deciding between tangentially sectioned Gleason pattern 3 versus poorly formed glands of Gleason pattern 4 on needle biopsy, which, they acknowledge, has been reported in other cohorts as well. This pathologic gray zone between Gleason score 6 and score 7 tumors could account in part for the wide distribution of molecular risk scores in individual clinical risk categories based on Gleason grade (ie, a patient with an NCCN low-risk cancer has a 77% average probability of favorable pathology at the time of prostatectomy, but with the addition of GPS, that same patient has a probability of favorable pathology ranging from 55% to 86%). An additional contributing factor to the likelihood that Gleason score 6 cancers are becoming more biologically homogenous and Gleason score 7 cancers are increasingly heterogeneous is the ongoing Gleason grade migration that has been reported in both the United States and Europe as a result of changes in how Gleason scores are assigned. Furthermore, it has been suggested that a small percentage of patients managed by AS may receive different treatment recommendations at follow-up biopsy based on the definition of histopathological progression used.

Validated molecular risk assessment tests provide an easily exportable, consistent level of objectivity, independent of local pathologic expertise, potentially rendering an even greater increase in prognostic precision than previously reported in cohorts undergoing centralized pathologic review. Their use can also potentially mitigate some of the interpatient variability that is introduced by varying pathologic interpretation. This added knowledge is particularly helpful in more confidently recommending AS to some patients with Gleason score 7 cancers with molecular risk scores that indicate a low likelihood of adverse pathology as well as providing additional peace of mind to a patient with very low-risk Gleason score 6 cancer who is choosing AS.

Multiparametric Magnetic Resonance Imaging as an Adjunct to Molecular Profiling
Multiparametric magnetic resonance imaging (MP-MRI) provides localization information to help guide the biopsy of suspicious areas, has a negative predictive value for Gleason score >6 of 80% to 90%, and increases the likelihood of finding a Gleason score 7 tumor on biopsy. Despite these valuable clinical characteristics, MP-MRI still cannot distinguish which of these tumors needs to be treated to decrease disease-specific mortality risk. In contrast to the molecular risk tests previously reviewed, to our knowledge there are no long-term follow-up data regarding MRI in the AS population. MP-MRI also does not detect all tumors. In addition, there is substantial “art of medicine” in MRI interpretation with an associated learning curve during implementation of this technology.
MP-MRI represents an important information-gathering tool during the initial evaluation for AS eligibility. However, to the best of our knowledge there is insufficient evidence to suggest that it can be used as a proxy for early repeat biopsy or to safely modify follow-up biopsy frequency in patients managed by AS. Rather, MP-MRI is likely to find its place as an adjunct to molecular risk profiling in further refining initial prognostic decision-making in patients managed by AS.56

**Does the Patient’s Race Matter?**
Recently, the safety of AS in African American (AA) patients has been called into question.57 The experience at Johns Hopkins demonstrates that AA men undergoing prostatectomy are more likely to have adverse pathology and BCR than their white counterparts of the same NCCN risk group.58,59 In AA men eligible for AS, higher rates of pathologically non-organ-confined disease as well as anteriorly located dominant nodules that may escape sampling by standard TRUS biopsy also have been reported.60,61 Jalloh et al examined 237 AA men in a cohort of 4231 patients classified with NCCN low-risk disease and found a significantly higher positive surgical margin rate in AA men, but no difference in rates of upstaging or upgrading at the time of prostatectomy.62 Offering AS to AA men has been debated in the literature with both the “pro” and “con” view suggesting that AS still can be offered to AA men if it is done in a careful manner while counseling patients regarding “elevated oncologic risks.”63,64

Molecular risk assessment is one possible way to help level this potentially uneven playing field for AA patients who meet the clinical criteria for AS. The initial validation studies of GPS did not explicitly account for racial variation and the percentage of AA patients was moderately low (12% and 10%, respectively, of patients in the biopsy study and prostatectomy study; only 3% in

### Figure 1. Incorporation of molecular risk profiling into active surveillance (AS) protocols. PSA indicates prostate-specific antigen.
the validation study). However, in a subsequent validation study of an independent cohort of 402 patients at 2 US military centers, 20% were AA (82 patients) and there were no significant racial differences noted with regard to the GPS distributions. GPS prediction of BCR and adverse pathology at the time of prostatectomy was found to be similar between white and AA patients (HR for time from biopsy to BCR per 20 GPS units, 2.97 vs 3.50, respectively; and OR for adverse pathology per 20 GPS units, 4.05 vs 2.86, respectively). The CCP score development studies and subsequent validation in AS-eligible cohorts do not report race distribution. However, the CCP score was found to be predictive of BCR and prostate cancer-specific mortality in a cohort of patients undergoing primary external-beam radiotherapy, approximately one-half of whom were AA. To the best of our knowledge, the racial distribution of patients used to develop the ProMark test is also currently unknown.

There is some encouraging evidence that molecular risk profiling may be powerful enough to overcome racial biases that are present with other forms of clinical risk stratification. Further application of these tests to validation cohorts with larger percentages of AA men, as well as other races, will hopefully increase confidence that these tests can be used with the same reliability regardless of an individual patient’s race.

Conclusions
In the setting of current clinical staging and risk prognostication methods, AS has rendered very positive results, with a variety of studies demonstrating cancer-specific survival rates that are at or near 100%. However, these studies represent a fraction of the number of men who are eligible for AS. To safely increase the number of patients who are managed with AS, the negative predictive value of whichever combination of clinical nomogram and molecular risk profiling is used must be high enough so that the cancer-specific survival rates of patients who are managed with AS do not fall below those of patients who are immediately treated. This is especially pertinent given the decreasing average age of the patient being managed by AS. We believe that molecular risk profiling can help to improve risk stratification for patients being evaluated for and subsequently followed on AS, while reducing some of the associated clinical and psychological burden.

FUNDING SUPPORT
No specific funding was disclosed.

CONFLICT OF INTEREST DISCLOSURES
Dr. Klein has acted as a paid consultant for GenomeDx, Genomic Health, and Metamark for work performed outside of the current study.

REFERENCES
1. Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33:272-277.
2. Bishop JT, Freedland SJ, Gerber L, et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol. 2014;192:409-414.
3. Shipitsin M, Small C, Choudhury S, et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer. 2014;111:1201-1212.
4. Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66:550-560.
5. American Cancer Society. Cancer Facts & Figures 2015. Available at: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index. Accessed April 28, 2015.
6. Mahmood U, Levy LB, Nguyen PL, et al. Current clinical presentation and treatment of localized prostate cancer in the United States. J Urol. 2014;192:1650-1656.
7. Li J, Djeuadj A, Soman A, Rim SH, Master VA. Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001–2007. Prostate Cancer. 2012;2012:e691380.
8. Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014;15:e484-e492.
9. De Carvalho TM, Heijnsdijk EA, de Koning HJ. Screening for prostate cancer in the US: Reduce the harms and keep the benefit. Int J Cancer. 2015;136:1600-1607.
10. Moyer VA; US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-134.
11. Cooperberg MR. Implications of the new AUA guidelines on prostate cancer detection in the U.S. Curr Urol Rep. 2014;15:420.
12. Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125-132.
13. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981-990.
14. Gulati R, Tsodikov A, Etzioni R, et al. Expected population impacts of discontinued prostate-specific antigen screening. Cancer. 2014;120:3519-3526.
15. Conti SL, D’Alera M, Fradet V, Cowan JE, Simko J, Carroll PR. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol. 2009;181:1628-1633; discussion 1633–1634.
16. Wong LM, Ferrara S, Alibhai SM, et al. Diagnostic prostate biopsy performed in a non-academic center increases the risk of re-classification at confirmatory biopsy for men considering active surveillance for prostate cancer. Prostate Cancer Prostatic Dis. 2015;18:69-74.
17. Elshafei A, Kartha G, Li Y, et al. Low risk patients benefit from extreme anterior apical sampling on initial biopsy for prostate cancer. J Urol. 2014;192:1650-1656.
18. D’Alera MA, Albertsen PC, Bangma C, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012;62:976-983.
19. Knezevic D, Goddard AD, Natraj N, et al. Analytical validation of the Oncotype DX prostate cancer assay—a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics. 2013;14:e90.
20. Cullen J, Ronner IL, Brand TC, et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol. 2014;66:550-560.
21. Dall’Era MA, Denes B, Lawrence HJ, et al. Clinical utility of a 17-gene genomic prostate score for treatment selection in men with newly diagnosed prostate cancer. J Clin Oncol. 2015; 33 (suppl; abstr 16124).

22. Badani KK, Kerner MJ, Febo PG, et al. The impact of a biopsy-based 17-gene genomic prostate score on treatment recommendations in men with newly diagnosed clinically prostate cancer who are candidates for active surveillance. Urol Pract. 2015; 2: 181-189.

23. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011; 12:245-255.

24. Cuzick J, Berney DM, Fisher G, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer. 2012;106:1095-1099.

25. Sommariva S, Tarricone R, Lazzeri M, Ricciardi W, Montorsi F. Prognostic value of the cell cycle progression score in patients with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2014 doi: 10.1016/j.euro.2014.11.038.

26. Cooperberg MR, Simklo JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013;31:1428-1434.

27. Crawford ED, Scholz MC, Kar AJ, et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin. 2014;30:1025-1031.

28. Shore N, Consecco R, Saltstein D, et al. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Curr Med Res Opin. 2014;30:547-553.

29. Blume-Jensen P, Berman DM, Rimm DL, et al. Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer [published online ahead of print March 2, 2015]. Clin Cancer Res.

30. Cooperberg MR. Long-term active surveillance for prostate cancer: answers and questions. J Clin Oncol. 2015;33:238-240.

31. National Comprehensive Cancer Network. NCCN Guidelines Version 1.2015 Prostate Cancer. Available at: http://www.nccn.org/professionals/physician_gls/pdf/guidelines.asp. Accessed January 28, 2015.

32. Eggener SE, Mueller A, Berglund RK, et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol. 2009;181:1635-1641.

33. King AC, Livermore A, Laurila TA, Huang W, Jarrad DF. Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer. Urol Oncol. 2013;31:739-743.

34. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014; 370:932-942.

35. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203-213.

36. Van der Bergh RC, Vasarainen H, van der Poel HG, et al. Short-term outcomes of the prospective multicentre “Prostate Cancer Research International: Active Surveillance” study. BJU Int. 2010; 105:956-962.

37. Bul M, Zhu X, Valdagni R, et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol. 2013;63:597-603.

38. Ehdaiie B, Vertosick E, Spaliviero M, et al. The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance. J Urol. 2014;191:660-664.

39. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011; 186:1830-1834.

40. Long Q, Xu J, Ounoukoy A, et al. Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence. Cancer Res. 2014;74:3228-3237.

41. Peng Z, Andersson K, Lindholm J, et al. Operator dependent choice of prostate cancer biopsy has limited impact on a gene signature analysis for the highly expressed genes IGFBP3 and F3 in prostate cancer epithelial cells. PLoS One. 2014;9:e109610.

42. Esermer LJ, Thompson IM Jr, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA. 2013; 310:797-799.

43. Goodman M, Ward KC, Ounoukoy AO, et al. Frequency and determinants of disagreement and error in Gleason scores: a population-based study of prostate cancer. Prostate. 2012;72:1389-1398.

44. Berney DM, Algabe F, Camparo P, et al. Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists. Virchows Arch. 2014;464:583-587.

45. McKenney JK, Simko J, Bonham M, et al. The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. J Urol. 2011;186:465-469.

46. Allsbrook WC Jr, Mangold KA, Johnson MH, et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol. 2001;32:74-80.

47. Weiser AB, Etrioni R, Eggener SE. Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance. Eur Urol. 2014;66:611-612.

48. Danneman D, Drevin L, Robinson D, Statton P, Egevad L. Gleason inflation 1998-2011: a registry study of 97,168 men. BJU Int. 2015; 115:248-255.

49. Epstein JJ, Allsbrook WC Jr, Amin MB, Egevad LL, ISUP Grading Coordinating Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29:1228-1242.

50. Thomsen FB, Marcusen N, Berg KD, et al. Repeated biopsies in patients with prostate cancer on active surveillance: clinical implications of interobserver variation in histopathological assessment. BJU Int. 2015;115:599-605.

51. Abdi H, Pourmalek F, Zargar H, et al. Multiparametric magnetic resonance imaging enhances detection of significant tumor in patients on active surveillance for prostate cancer. Urology. 2015;85: 423-429.

52. Mullins JK, Bonekamp D, Landis P, et al. Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU Int. 2013;111:1037-1045.

53. Schoots IG, Petrides N, Giganti F, et al. Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol. 2015;67:627-636.

54. Dianat SS, Carter HB, Pienta KJ, et al. Magnetic resonance-invisible versus magnetic resonance-visible prostate cancer in active surveillance: a preliminary report on disease outcomes. Urology. 2015;85: 147-154.

55. Gazeri G, Wadhwa K, Barrett T, et al. Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI-transectal ultrasonography (TRUS) fusion-guided transperineal prostate biopsies as a validation tool [published online ahead of print August 7, 2014]. BJU Int. doi: 10.1111/bju.12892.

56. Arsov C, Jankowiak F, Hiester A, et al. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy–a pilot study. Anticancer Res. 2014;34:2459-2466.

57. Silberstein JL, Feibus AH, Maddox MM, et al. Active surveillance of prostate cancer in African American men. Urology. 2014;84:1255-1261.

58. Faisal FA, Sundi D, Cooper JL, et al. Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up. Urology. 2014;84:1434-1441.

59. Sundi D, Ross AE, Humphreys EB, et al. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol. 2013;31:2991-2997.

60. Ha YS, Salmasi A, Karellas M, et al. Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance. Urology. 2013;81:831-835.

61. Sundi D, Kryvenko ON, Carter HB, Ross AE, Epstein JJ, Schaeffer EM. Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals
distinct zonal distribution of cancer in black American men. 

J Urol. 2014;191:60-67.

62. Jalloh M, Myers F, Cowan JE, Carroll PR, Cooperberg MR. 
Racial variation in prostate cancer upgrading and upstaging 
among men with low-risk clinical characteristics. Eur Urol. 2015; 
67:451-457.

63. Moul JW. Active surveillance for African-American men with pros-
tate cancer: of course! Pro. Oncology (Williston Park). 2014;28:82, 
84-85.

64. Sundi D, Schaeffer EM. Active surveillance for African-American 
men with prostate cancer: proceed with caution. Con. Oncology (Wil-
liston Park). 2014;28:83, 85.

65. Freedland SJ, Gerber L, Reid J, et al. Prognostic utility of cell cycle pro-
gression score in men with prostate cancer after primary external beam 
radiation therapy. Int J Radiat Oncol Biol Phys. 2013;86:848-853.

66. Liu D, Lehmann HP, Frick KD, Carter HB. Active surveillance ver-
sus surgery for low risk prostate cancer: a clinical decision analysis. 
J Urol 2012;187:1241-1246.